Christopher P. Lowe's Insider Trades & SAST Disclosures
Christopher P. Lowe's most recent trade in Vincerx Pharma Inc was a trade of 18,400 Common Stock done at an average price of $1.6 . Disclosure was reported to the exchange on Aug. 24, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Christopher P. Lowe.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vincerx Pharma Inc | Christopher P. Lowe | Director | Purchase of securities on an exchange or from another person at price $ 1.65 per share. | 24 Aug 2022 | 18,400 | 28,400 | - | 1.6 | 30,299 | Common Stock |
| Vincerx Pharma Inc | Christopher P. Lowe | Director | Purchase of securities on an exchange or from another person at price $ 1.65 per share. | 24 Aug 2022 | 11,600 | 40,000 | - | 1.6 | 19,139 | Common Stock |
| Vincerx Pharma Inc | Christopher P. Lowe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Quince Therapeutics Inc | Christopher P. Lowe | Interim CEO, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 175,000 | 265,000 (0%) | 0% | 0 | Common Stock | |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2021 | 30,000 | 103,294 | - | - | Stock Option (right to buy) | |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.23 per share. | 16 Nov 2021 | 30,000 | 90,000 (0%) | 0% | 2.2 | 66,900 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 98.50 per share. | 05 Oct 2021 | 4,963 | 60,000 (0%) | 0% | 98.5 | 488,856 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2021 | 4,963 | 95,037 | - | - | Stock Option (Right to Buy) | |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.85 per share. | 05 Oct 2021 | 4,963 | 64,963 (0%) | 0% | 54.9 | 272,221 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.23 per share. | 16 Aug 2021 | 30,000 | 60,000 (0%) | 0% | 2.2 | 66,900 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2021 | 30,000 | 133,294 | - | - | Stock Option (right to buy) | |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.23 per share. | 16 Aug 2021 | 22,000 | 52,000 (0%) | 0% | 2.2 | 49,060 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2021 | 22,000 | 163,294 | - | - | Stock Option (right to buy) | |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 94.23 per share. | 16 Aug 2021 | 9,158 | 42,842 (0%) | 0% | 94.2 | 862,958 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 95.02 per share. | 16 Aug 2021 | 7,335 | 35,507 (0%) | 0% | 95.0 | 696,972 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 96.32 per share. | 16 Aug 2021 | 2,330 | 33,177 (0%) | 0% | 96.3 | 224,426 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 98.90 per share. | 16 Aug 2021 | 2,077 | 30,000 (0%) | 0% | 98.9 | 205,415 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 97.28 per share. | 16 Aug 2021 | 1,100 | 32,077 (0%) | 0% | 97.3 | 107,008 | Common Stock |
| Vincerx Pharma Inc | Christopher P. Lowe | Director | Purchase of securities on an exchange or from another person at price $ 12.59 per share. | 29 Jun 2021 | 6,400 | 6,400 | - | 12.6 | 80,576 | Common Stock |
| Vincerx Pharma Inc | Christopher P. Lowe | Director | Purchase of securities on an exchange or from another person at price $ 12.66 per share. | 29 Jun 2021 | 3,600 | 10,000 | - | 12.7 | 45,576 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2021 | 30,000 | 185,294 | - | - | Stock Option (right to buy) | |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.23 per share. | 28 Jun 2021 | 30,000 | 30,000 (0%) | 0% | 2.2 | 66,900 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2021 | 20,000 | 215,594 | - | - | Stock Option (right to buy) | |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.23 per share. | 28 Jun 2021 | 20,000 | 20,000 (0%) | 0% | 2.2 | 44,600 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 53.39 per share. | 28 Jun 2021 | 7,724 | 12,276 (0%) | 0% | 53.4 | 412,384 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 54.13 per share. | 28 Jun 2021 | 7,079 | 5,197 (0%) | 0% | 54.1 | 383,186 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 55.11 per share. | 28 Jun 2021 | 4,153 | 1,044 (0%) | 0% | 55.1 | 228,872 | Common Stock |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 56.16 per share. | 28 Jun 2021 | 1,044 | 0 (0%) | 0% | 56.2 | 58,631 | Common Stock |
| Vincerx Pharma Inc | Christopher P. Lowe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Quince Therapeutics Inc | Christopher P. Lowe | COO & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2021 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Vincerx Pharma Inc | Christopher P. Lowe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2020 | 6,667 | 6,667 | - | - | Stock Option (right to buy) | |
| Quince Therapeutics Inc | Christopher P. Lowe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2020 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Quince Therapeutics Inc | Christopher P. Lowe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2020 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges